2 terminated, 1 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow olinvacimab: new trials by email Literature Review of olinvacimab trials Research Report on olinvacimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olinvacimab With Pembrolizumab in Patients With mTNBC Olinvacimab - Metastatic Triple-Negative Breast Cancer | Phase 2 | Terminated | PharmAbcine | 19 | 2021-09-30 | 2025-12-30 |
| TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab TTAC-0001 - Recurrent Glioblastoma | Phase 2 | Terminated | PharmAbcine | 19 | 2019-11-13 | 2022-08-18 |
| Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma TTAC-0001 - Recurrent Glioblastoma | Phase 2 | Completed | PharmAbcine | 12 | 2016-02-04 | 2021-01-27 |
Glioblastoma (2) · Triple Negative Breast Neoplasms (1)
PharmAbcine (3)
Australia (2) · United States (1)
Brenton Seidl, Ph.D, MD (1) · Claire Beecroft, Ph.D, MD (1) · Daphne Day, Ph.D, MD (1) · Dhanusha Sabanathan, Ph.D, MD (1)